Together we can make RET-positive cancer a chronic disease!

RET is a mutation that causes cancer cells to multiply and spread. RET alterations occur in 2% of non-small cell lung cancers (NSCLC), with a higher percentage of patients being younger (<60) and never-smokers. RET alterations also drive a range of other cancers, including thyroid, pancreatic, colorectal, bladder, and breast cancers.

Your donation helps patients like Brittany.

Brittany, a stage IV RET-positive NSCLC survivor, was diagnosed at age 36. Listen to Brittany's story.

RET-specific medical research is vital.

RET patients are counting on the development of new medications to overcome cancer resistance mechanisms and, someday, make RET-positive cancer manageable with daily medication.

Through awareness, research, and patient support, RETpositive is working to transform RET-driven cancer from a terminal disease to a chronic and manageable one.

We support research that will advance our understanding of RET-driven cancers and increase the number and quality of cancer treatments for all RET patients.

Over $2.2 million co-funded for medical research since 2022.

We harness the scientific and institutional capacity of a range of partners to identify and fund research projects demonstrating the greatest potential to benefit RET+ patients. Learn more about our co-funded research projects.

Every donation, no matter the size, makes a difference!

Help us fund the next round of RET Awards!

Research is hope!

Team Leaderboard

Team Members